

Date: 31-07-2020

To
Mr. BhushanMokashi
Manager
Bombay Stock Exchange Limited,
PhirozeJeeJeebhoy Towers,
Dalal Street, MUMBAI – 400 001.

Sir,
Sub: Outcome of the Board Meeting – Reg.
Ref: Our Company code no: 532041.

The following is the Outcome of the Board Meeting of the Company held on 31st July, 2020 at 02.00 P.M. at the registered office of the Company:

- 1 The Board has approved the un-audited financial results of the company for the quarter ended on 30th June, 2020.
- 2 The board has approved to convene the 28th Annual General Meeting of the Company on 30th September 2020 at 10.00 A.M at the Registered Office of the Company.
- 3 The Board approved the Notice of Annual General Meeting and Directors report and authorised the Chairman and Managing Director to sign and despatch the Annual reports to all the concerned.
- 4 The Board ascertained Mr. J Varun Varma as Director retiring by rotation and recommended for his re appointment.

We are herewith enclosing un-audited financial results of the company & Limited Review Report issued by the auditor for the quarter ended 30.06.2020, as per Regulation 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,
For **Hindustan Bio Sciences Limited**

VENKATA RAMA
MOHAN RAJU
JAMPANA

Digitally signed by VENKATA
RAMA MOHAN RAJU JAMPANA
Date: 2020.07.31 16:08:34
+05'30'

J V R Mohan Raju
Managing Director

HINDUSTAN BIO SCIENCES LIMITED
 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034
 Phone No. 23555161, Fax 40205171
STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE,2020

(Rs. In lakhs)

Sl. No.	Particulars	Quarter ended			Year ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
1	Income from Operations				
	(a) Revenue from operations	55.48	84.66	57.52	194.33
	(b) Other Income	-	-	-	-
	Total Revenue (1)	55.48	84.66	57.52	194.33
2	Expenses				
	(a) cost of material consumed	-	-	-	-
	(b) Purchases of Stock -in-trade	20.48	84.16	49.57	152.69
	(c) Changes in Inventories of finished goods,Stock - in-Trade and Work-in-Progress	16.82	(25.61)	(19.07)	(22.63)
	(d) Employee Benefit Expenses	6.17	6.85	6.34	25.73
	(e) Finance Costs	0.23	0.19	0.17	0.82
	(f) Selling Expenses	0.38	0.10	0.09	0.55
	(g) Depreciation and amortisation Expenses	0.16	0.24	0.28	1.14
	(h) Other Expenses	6.20	8.21	6.24	24.38
	Total Expenses(2)	50.44	74.14	43.62	182.68
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	5.04	10.52	13.90	11.65
4	Exceptional items	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	5.04	10.52	13.90	11.65
6	Tax Expenses				
	(a) Current Tax	-	1.82	-	1.82
	(b) Deferred Tax	-	1.74	-	1.74
7	Profit /(Loss) for the period from continuing operations(5-6)	5.04	6.96	13.90	8.09
8	Profit /(Loss) from discontinued operations	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-
11	Profit/(Loss) for the period(7+10)	5.04	6.96	13.90	8.09
12	Other Comprehensive Income				
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	5.04	6.96	13.90	8.09
14	Paid up Equity Capital(Face value of Rs. 10/- each)	1,025.08	1,025.08	1,025.08	1,025.08
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				(800.64)
16	Earnings per equity share for continuing operations				
	(A) Basic	0.05	0.07	0.14	0.08
	(B) Diluted	0.05	0.07	0.14	0.08
17	Earnings per equity share for discontinuing operations				
	(A) Basic	-	-	-	-
	(B) Diluted	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations				
	(A) Basic	0.05	0.07	0.14	0.08
	(B) Diluted	0.05	0.07	0.14	0.08

Notes:

- 1 The Un-audited Financial Results were taken on record by the the Board of Directors in their meeting held on 31.07.2020
- 2 Previous year figures have been regrouped wherever necessary.
- 3 The Central Government declared a lockdown on 23rd March,2020 due to COVID-19 outbreak in India. The operations of the company has been suspended from the date of lockdown till 11th May, 2020. The company has taken all safety measures and restarted its operations . The management is cautiously monitoring the pandemic situation and has considered both internal and external information in determining the effects on the carrying amounts of receivables, inventories, trade payables and other current assets and liabilities. However the actual impact of COVID-19 may differ from estimates and the management is cautiously monitoring the same.

Place: Hyderabad
 Date : 31.07.2020

For HINDUSTAN BIO SCIENCES LIMITED

VENKATA RAMA MOHAN | Digitally signed by VENKATA RAMA
 MOHAN RAJU JAMPANA
 DN: cn=VENKATA RAMA MOHAN RAJU JAMPANA, o=HINDUSTAN BIO SCIENCES LIMITED, email=venkataramu@hbsl.com

J.V.R. MOHAN RAJU
 Managing Director



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
M/S HINDUSTAN BIO SCIENCES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of M/S **HINDUSTAN BIO SCIENCES LIMITED** (the "Company"), for the quarter ended June 30, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

We draw your attention to note no. 3 of the statement, dealing with uncertainties due to COVID-19 pandemic situation where in the management's analysis and estimates were made on impact of COVID-19 on financial reporting, receivables, assets and future operations of the company. The actual impact of the pandemic situation may differ from the estimates made by the management.

Our conclusion is not modified in respect of this matter.

Place: Hyderabad
Date: July 31, 2020

For C.RAMACHANDRAM & CO
Chartered Accountants

FR.No. 002864S

RAMACHANDRDigitally signed by
AM CHELIKAMRAMACHANDRAM CHELIKAM
Date: 2020.07.31 16:05:56
+05'30'

C.RAMACHANDRAM

Partner

Membership No. 025834

UDIN: 20025834AAAAMK7087